Aziz Mottiwala, Chief Commercial Officer at Tarsus Pharmaceuticals, Inc. (TARS), sold 17,500 shares at $43.76 ($766K) on 2025-06-09, disclosed to the SEC on 2025-06-11.
Scheduled sale ($766k) by Chief Commercial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| TARS | SELL | 2024-03-19 | $292K | — | Filing → |
| TARS | SELL | 2023-07-21 | $48K | — | Filing → |
| TARS | SELL | 2023-06-12 | $2K | — | Filing → |